Patents by Inventor Ernest Mui

Ernest Mui has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20130324555
    Abstract: The present invention is directed to the method of use of effective pharmaceutical formulations for the treatment of diseases caused by apicomplexan parasites, said formulation comprised of a salicylanilide or salicylanilide derivative, disclosed herein, alone or in combination with one or more other active or excipient pharmaceutical substances. The present invention is further directed to the method of use of effective pharmaceutical formulations for the treatment of diseases caused by apicomplexan parasites, said formulation comprised of a combination of salicylanilides or salicylanilide derivatives, disclosed herein. The present invention is further directed to the method of use of effective pharmaceutical formulations for the treatment of diseases caused by apicomplexan parasites, said formulation comprised of a combination of salicylanilides or salicylanilide derivatives, disclosed herein, further comprised of one or more active or excipient pharmaceutical substances.
    Type: Application
    Filed: May 29, 2013
    Publication date: December 5, 2013
    Inventors: Richard Delarey Wood, Rima McLeod, Ernest Mui, Alina Fomovska, William Welsh
  • Patent number: 8575126
    Abstract: Pharmaceutical formulations of antisense peptide-conjugated phosphorodiamidate morpholino olgomers and methods of use for treatment of apicomplexan infections are disclosed. The invention is particularly directed to treatment of Toxoplasma gondii infections.
    Type: Grant
    Filed: June 27, 2012
    Date of Patent: November 5, 2013
    Inventors: Rima McLeod, Bo Shiun Lai, William Witola, Kamal El Bissati, Ernest Mui, Hong Moulton, Jonathan B Rothbard, Jon D Moulton
  • Publication number: 20130053427
    Abstract: Pharmaceutical formulations of antisense peptide-conjugated phosphorodiamidate morpholino olgomers and methods of use for treatment of apicomplexan infections are disclosed. The invention is particularly directed to treatment of Toxoplasma gondii infections.
    Type: Application
    Filed: June 27, 2012
    Publication date: February 28, 2013
    Inventors: Rima McLeod, Bo Shiun Lai, William Witola, Kamal El Bissati, Ernest Mui, Hong Moulton, Jonathan B. Rothbard, Jon D. Moulton
  • Publication number: 20050142113
    Abstract: This invention relates uses of components of plant-like metabolic pathways not including psbA or PPi phosphofructokinase and not generally operative in animals or encoded by the plastid DNA, to develop compositions that interfere with Apicomplexan growth and survival. Components of the pathways include enzymes, transit peptides and nucleotide sequences encoding the enzymes and peptides, or promoters of these nucleotide sequences to which antibodies, antisense molecules and other inhibitors are directed. Diagnostic and therapeutic reagents and vaccines are developed based on the components and their inhibitors.
    Type: Application
    Filed: April 14, 2004
    Publication date: June 30, 2005
    Inventors: Rima McLeod, Craig Roberts, Fiona Roberts, Jennifer Johnson, Michael Kirisits, David Ferguson, Russell Lyons, Ernest Mui, Doug Mack, Benjamin Samuel, Piotr Gornicki, Ellen Zuther
  • Patent number: 6737237
    Abstract: This invention relates uses of Toxoplasma gondii chorismate synthase, a component components of plant-like metabolic pathways not including psbA or PPi phosphofructokinase and not generally operative in animals or encoded by the plastid DNA, in assays to develop compositions that interfere with Apicomplexan growth and survival. Components of the pathways include enzymes, transit peptides and nucleotide sequences encoding the enzymes and peptides, or promoters of these nucleotide sequences to which antibodies, antisense molecules and other inhibitors are directed. Diagnostic and therapeutic reagents and vaccines are developed based on T. gondii chorismate synthase and its inhibitors.
    Type: Grant
    Filed: August 3, 2000
    Date of Patent: May 18, 2004
    Assignee: Apicomplexan Therapeutics, LLC
    Inventors: Rima L. McLeod, Craig W. Roberts, Fiona Roberts, Jennifer J. Johnson, Michael Kirisits, David Ferguson, Russell Lyons, Ernest Mui, Doug Mack, Benjamin Samuel, Piotr Gornicki, Ellen Zuther
  • Publication number: 20030186352
    Abstract: This invention relates uses of components of plant-like metabolic pathways not including psbA or PPi phosphofructokinase and not generally operative in animals or encoded by the plastid DNA, to develop compositions that interfere with Apicomplexan growth and survival. Components of the pathways include enzymes, transit peptides and nucleotide sequences encoding the enzymes and peptides, or promoters of these nucleotide sequences to which antibodies, antisense molecules and other inhibitors are directed. Diagnostic and therapeutic reagents and vaccines are developed based on the components and their inhibitors.
    Type: Application
    Filed: October 10, 2002
    Publication date: October 2, 2003
    Inventors: Rima L. McLeod, Michael Kirisits, Craig W. Roberts, Doug Mack, Ernest Mui, John Barnwell, John Dame, Jane Carlton, Paul Bartlett, Suzanna Parle